Lateral Flow Assay Detects Leprosy Immune Response
By LabMedica International staff writers Posted on 22 May 2014 |

Image: Packard FluoroCount microtiter-plate reader adapted to read lateral flow strips (Photo courtesy of PerkinElmer).

Image: The ESEQuant Lateral Flow Assay Reader (Photo courtesy of Qiagen).
Field-applicable tests detecting asymptomatic Mycobacterium leprae infection or predicting progression to leprosy are urgently required to determine both cellular and humoral immunity.
Leprosy, a curable infectious disease caused by M. leprae that affects the skin and peripheral nerves, is one of the six diseases considered as a major threat in developing countries as continued transmission in endemic areas likely occurs from the large reservoir of individuals who are infected subclinically.
Infectious disease specialists at the Leiden University Medical Center (The Netherlands) with colleagues in Ethiopia recruited for their study human immunodeficiency virus (HIV)-negative, newly diagnosed untreated leprosy patients, and healthy endemic controls from October 2011 until November 2012. Leprosy was diagnosed based on clinical, bacteriological and histological observations and classified by a skin biopsy.
The combined diagnostic value of interferon (IFN)-γ induced protein 10 (IP-10), interleukin-10 (IL-10) and anti-Phenolic Glycolipid-I (PGL-I) antibodies was tested using M. leprae-stimulated blood of leprosy patients and endemic controls (EC). For reduction of the overall test-to-result time, the minimal whole blood assay time required to detect distinctive responses was investigated. To accommodate Lateral Flow Assays (LFAs) for field settings, dry-format LFAs for IP-10 and anti-PGL-I antibodies were developed allowing storage and shipment at ambient temperatures. Additionally, a multiplex LFA-format was applied for simultaneous detection of anti-PGL-I antibodies and IP-10. For improved sensitivity and quantitation, upconverting phosphor (UCP) reporter technology was applied in all LFAs.
After immunochromatography, LF strips are scanned in a Packard FluoroCount microtiter- plate reader (PerkinElmer; Waltham, MA, USA) adapted with an infrared laser. Upon IR excitation at 980 nm, UCP reporter particles emit green light detectable using a 550 nm band pass filter. For strip analysis in Ethiopia, a lightweight portable LF strip reader with UCP capability was used (UCP-Quant, an ESEQuant LFR reader custom adapted with IR diode; (QIAGEN Lake Constance GmbH; Stockach, Germany).
Single and multiplex UCP-LFAs correlated well with enzyme-linked immunosorbent assays (ELISAs) run in parallel. The performance of dry reagent assays and portable, lightweight UCP-LF strip readers indicated excellent field-robustness. Notably, detection of IP-10 levels in stimulated samples allowed a reduction of the whole blood assay time from 24 hours to six hours. Moreover, IP-10/IL-10 ratios in unstimulated plasma differed significantly between patients and endemic controls, indicating the feasibility to identify M. leprae infection in endemic areas.
The authors concluded that dry-format UCP-LFAs are low-tech, robust assays allowing detection of relevant cytokines and antibodies in response to M. leprae in the field. The high levels of IP-10 and the required shorter whole blood assay time, render this cytokine useful to discriminate between leprosy patients and endemic controls. The study was published on May 8, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Leiden University Medical Center
PerkinElmer
QIAGEN Lake Constance GmbH
Leprosy, a curable infectious disease caused by M. leprae that affects the skin and peripheral nerves, is one of the six diseases considered as a major threat in developing countries as continued transmission in endemic areas likely occurs from the large reservoir of individuals who are infected subclinically.
Infectious disease specialists at the Leiden University Medical Center (The Netherlands) with colleagues in Ethiopia recruited for their study human immunodeficiency virus (HIV)-negative, newly diagnosed untreated leprosy patients, and healthy endemic controls from October 2011 until November 2012. Leprosy was diagnosed based on clinical, bacteriological and histological observations and classified by a skin biopsy.
The combined diagnostic value of interferon (IFN)-γ induced protein 10 (IP-10), interleukin-10 (IL-10) and anti-Phenolic Glycolipid-I (PGL-I) antibodies was tested using M. leprae-stimulated blood of leprosy patients and endemic controls (EC). For reduction of the overall test-to-result time, the minimal whole blood assay time required to detect distinctive responses was investigated. To accommodate Lateral Flow Assays (LFAs) for field settings, dry-format LFAs for IP-10 and anti-PGL-I antibodies were developed allowing storage and shipment at ambient temperatures. Additionally, a multiplex LFA-format was applied for simultaneous detection of anti-PGL-I antibodies and IP-10. For improved sensitivity and quantitation, upconverting phosphor (UCP) reporter technology was applied in all LFAs.
After immunochromatography, LF strips are scanned in a Packard FluoroCount microtiter- plate reader (PerkinElmer; Waltham, MA, USA) adapted with an infrared laser. Upon IR excitation at 980 nm, UCP reporter particles emit green light detectable using a 550 nm band pass filter. For strip analysis in Ethiopia, a lightweight portable LF strip reader with UCP capability was used (UCP-Quant, an ESEQuant LFR reader custom adapted with IR diode; (QIAGEN Lake Constance GmbH; Stockach, Germany).
Single and multiplex UCP-LFAs correlated well with enzyme-linked immunosorbent assays (ELISAs) run in parallel. The performance of dry reagent assays and portable, lightweight UCP-LF strip readers indicated excellent field-robustness. Notably, detection of IP-10 levels in stimulated samples allowed a reduction of the whole blood assay time from 24 hours to six hours. Moreover, IP-10/IL-10 ratios in unstimulated plasma differed significantly between patients and endemic controls, indicating the feasibility to identify M. leprae infection in endemic areas.
The authors concluded that dry-format UCP-LFAs are low-tech, robust assays allowing detection of relevant cytokines and antibodies in response to M. leprae in the field. The high levels of IP-10 and the required shorter whole blood assay time, render this cytokine useful to discriminate between leprosy patients and endemic controls. The study was published on May 8, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Leiden University Medical Center
PerkinElmer
QIAGEN Lake Constance GmbH
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more